OBJECTIVES: Methotrexate (MTX) functions as an antiproliferative agent in cancer and an anti-inflammatory drug in rheumatoid arthritis (RA). Although macrophages critically contribute to RA pathology, their response to MTX remains unknown. As a means to identify MTX response markers, we have explored its transcriptional effect on macrophages polarised by GM-CSF (GM-MØ) or M-CSF (M-MØ), which resemble proinflammatory and anti-inflammatory macrophages found in RA and normal joints, respectively. METHODS: The transcriptomic profile of both human macrophage subtypes exposed to 50 nM of MTX under long-term and short-term schedules were determined using gene expression microarrays, and validated through quantitative real time PCR and ELISA. The molecular pathway involved in macrophage MTX-responsiveness was determined through pharmacological, siRNA-mediated knockdown approaches, metabolomics for polyglutamylated-MTX detection, western blot, and immunofluorescence on RA and normal joints. RESULTS: MTX exclusively modulated gene expression in proinflammatory GM-MØ, where it influenced the expression of 757 genes and induced CCL20 and LIF at the mRNA and protein levels. Pharmacological and siRNA-mediated approaches indicated that macrophage subset-specific MTX responsiveness correlates with thymidylate synthase (TS) expression, as proinflammatory TS+ GM-MØ are susceptible to MTX, whereas anti-inflammatory TSlow/- M-MØ and monocytes are refractory to MTX. Furthermore, p53 activity was found to mediate the TS-dependent MTX-responsiveness of proinflammatory TS+ GM-MØ. Importantly, TS and p53 were found to be expressed by CD163+/TNFα+ GM-CSF-polarised macrophages from RA joints but not from normal synovium. CONCLUSIONS: Macrophage response to MTX is polarisation-dependent and determined by the TS-p53 axis. CCL20 and LIF constitute novel macrophage markers for MTX responsiveness in vitro. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVES:Methotrexate (MTX) functions as an antiproliferative agent in cancer and an anti-inflammatory drug in rheumatoid arthritis (RA). Although macrophages critically contribute to RA pathology, their response to MTX remains unknown. As a means to identify MTX response markers, we have explored its transcriptional effect on macrophages polarised by GM-CSF (GM-MØ) or M-CSF (M-MØ), which resemble proinflammatory and anti-inflammatory macrophages found in RA and normal joints, respectively. METHODS: The transcriptomic profile of both human macrophage subtypes exposed to 50 nM of MTX under long-term and short-term schedules were determined using gene expression microarrays, and validated through quantitative real time PCR and ELISA. The molecular pathway involved in macrophage MTX-responsiveness was determined through pharmacological, siRNA-mediated knockdown approaches, metabolomics for polyglutamylated-MTX detection, western blot, and immunofluorescence on RA and normal joints. RESULTS:MTX exclusively modulated gene expression in proinflammatory GM-MØ, where it influenced the expression of 757 genes and induced CCL20 and LIF at the mRNA and protein levels. Pharmacological and siRNA-mediated approaches indicated that macrophage subset-specific MTX responsiveness correlates with thymidylate synthase (TS) expression, as proinflammatory TS+ GM-MØ are susceptible to MTX, whereas anti-inflammatory TSlow/- M-MØ and monocytes are refractory to MTX. Furthermore, p53 activity was found to mediate the TS-dependent MTX-responsiveness of proinflammatory TS+ GM-MØ. Importantly, TS and p53 were found to be expressed by CD163+/TNFα+ GM-CSF-polarised macrophages from RA joints but not from normal synovium. CONCLUSIONS: Macrophage response to MTX is polarisation-dependent and determined by the TS-p53 axis. CCL20 and LIF constitute novel macrophage markers for MTX responsiveness in vitro. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Fedra Luciano-Mateo; Anna Hernández-Aguilera; Noemi Cabre; Jordi Camps; Salvador Fernández-Arroyo; Jose Lopez-Miranda; Javier A Menendez; Jorge Joven Journal: Nutrients Date: 2017-02-10 Impact factor: 5.717
Authors: Anna Ohradanova-Repic; Christian Machacek; Celine Charvet; Franck Lager; Delphine Le Roux; René Platzer; Vladimir Leksa; Goran Mitulovic; Thomas R Burkard; Gerhard J Zlabinger; Michael B Fischer; Vincent Feuillet; Gilles Renault; Stephan Blüml; Miroslav Benko; Miloslav Suchanek; Johannes B Huppa; Takami Matsuyama; Artur Cavaco-Paulo; Georges Bismuth; Hannes Stockinger Journal: Front Immunol Date: 2018-04-27 Impact factor: 7.561
Authors: Ittai B Muller; Marry Lin; Willem F Lems; Marieke M Ter Wee; Anna Wojtuszkiewicz; Michael T Nurmohamed; Jacqueline Cloos; Yehuda G Assaraf; Gerrit Jansen; Robert de Jonge Journal: Rheumatology (Oxford) Date: 2021-03-02 Impact factor: 7.580
Authors: Maarten M Steinz; Aiarpi Ezdoglian; Fatemeh Khodadust; Carla F M Molthoff; Madduri Srinivasarao; Philip S Low; Gerben J C Zwezerijnen; Maqsood Yaqub; Wissam Beaino; Albert D Windhorst; Sander W Tas; Gerrit Jansen; Conny J van der Laken Journal: Front Immunol Date: 2022-02-02 Impact factor: 7.561
Authors: Durga M S H Chandrupatla; Carla F M Molthoff; Adriaan A Lammertsma; Conny J van der Laken; Gerrit Jansen Journal: Drug Deliv Transl Res Date: 2019-02 Impact factor: 4.617